Skip links

05.02.2025

Why do Clinical Trails Fail and How we can prevent?

Clinical trial management for pharmaceuticals and medical devices is a complex, resource-intensive endeavor. Many factors contribute to trial failures, including lack of efficacy, safety concerns, funding constraints, poor manufacturing protocols, regulatory challenges, and patient recruitment issues. The consequences of failure extend beyond financial loss, affecting prior research efforts, time investment, and potential treatment alternatives. Therefore, ensuring accurate results at each stage through effective clinical trial management is crucial for determining whether a trial should continue.

Understanding the Success Rates of Clinical Trials

Clinical trials progress through multiple phases before gaining regulatory approval. However, the likelihood of a drug successfully passing each stage remains low:

  • Drugs progressing from Phase I to FDA approval: 7.9%
  • Phase II to Phase III transition: 28.9%
  • Phase III to NDA/BLA submission: 57.8%
  • Likelihood of FDA approval after NDA/BLA submission: 90.6%

Given these statistics, identifying and addressing the factors that contribute to clinical trial failures is essential.

Major Challenges in clinical trial

A number of causes contribute to clinical trial failures, such as difficulties in biology and pharmacology, poor study design, problems unique to a treatment area, and obstacles related to regulations and compliance. Trial results may be jeopardised by inadequate translation between human and animal models as well as a lack of knowledge about pharmacodynamics (PD) and pharmacokinetics (PK). Failures are also caused by defects in the study design, such as inadequate evaluation methods, improper trial populations, and inaccurate dosage selection. Oncology and orphan medication studies are known to have high failure rates. Trial termination may also result from inadequate protocol designs and noncompliance with regulatory standards.

Unpredictable placebo effects and patient responses, handling large, diverse datasets, a lack of knowledge about illness causes and medication combinations, and time and money restrictions that result in trial delays and underfunding are some of the major challenges in clinical trials. Trial development can also be hampered by bad project management, which is typified by poor stakeholder inclusion, unrealistic timeframes, insufficient team motivation, and poor risk forecasting. Inefficiencies are also caused by a high staff turnover rate, inexperience collaborating with others, and an uneven team structure. Trial flow is disrupted by complicated protocols with too many endpoints and frequent revisions, and site motivation is decreased by strict eligibility requirements that frequently clash with enrolment goals. Study variability and mistakes are increased by poor training and verification, which includes inconsistent assessment methods and insufficient competency-based training.  Ethical issues such as fraud, dishonesty, and regulatory breaches further compromise trial integrity, damaging stakeholder reputations and public trust. Addressing these challenges through strategic planning and execution is crucial for improving clinical trial success rates.

Strategies to Improve Clinical Trial Success

  1. Validate an Appropriate Clinical Trial Design
  • Utilize parallel or crossover studies for trial requirements, employ adaptable designs for flexibility, and optimize population size and inclusion/exclusion criteria.
  1. Apply Simulation and Modelling
  • To accelerate decision-making and lower trial expenses, utilise modelling to forecast clinical outcomes, PK/PD variability, and dosage. 
  1. Select the Right Efficacy Endpoints
  • The objective must be to incorporate biomarkers as surrogate endpoints for clinical benefit and ensure their regulatory acceptance.
  1. Incorporate Cross-Disciplinary Expertise
  • Foster collaboration between clinical scientists, biostatisticians, regulatory experts, and drug development teams

Partnering with Haleus to Minimize Clinical Trial Failure

Clinical trial failures can be significantly reduced through strategic planning, robust study designs, and efficient execution. Haleus provides comprehensive support at every stage of the trial process to enhance success rates and optimize resource utilization. Here, we offer expert study design and planning, ensuring rigorous, regulatory-compliant approaches for patient selection, dose determination, and endpoint selection. We employ a risk-based approach and data-driven strategies to maintain data integrity, ensure regulatory compliance, identify eligible patients, enhance engagement, and reduce dropout rates. Our team of clinical scientists, biostatisticians, regulatory experts, and operational specialist’s works collaboratively to streamline processes, optimize resource allocation, and transform trial challenges into opportunities for success.

 

Why do Clinical Trails Fail and How we can prevent?

ClinicalTrails

Share on :

Facebook
Twitter
LinkedIn